Dear Valued Patient: “Bye-Bye!”
Heart Sisters
JULY 7, 2024
Family physicians who are retiring or leaving the field now outnumber new medical school graduates choosing a career in family medicine. This reality just hit home for me.
Sun.Jul 07, 2024
81 
Trends in direct health care costs among US adults with atherosclerotic cardiovascular disease with and without diabetes
Cardiovascular Diabetology
JULY 7, 2024
Objective Population-based national data on the trends in expenditures related to coexisting atherosclerotic cardiovascular diseases (ASCVD) and diabetes is scarce. We assessed the trends in direct health care expenditures for ASCVD among individuals with and without diabetes, which can help to better define the burden of the co-occurrence of diabetes and ASCVD.
60 year old with chest pain, STEMI negative. What should the discharge diagnosis be?
Dr. Smith's ECG Blog
JULY 7, 2024
Written by Jesse McLaren A previously healthy 60 year old developed exertional chest pain with diaphoresis, and called EMS. Here’s the EMS ECG, digitized with PM cardio. What do you think? There’s sinus arrhythmia with normal conduction, normal axis and normal voltages. There’s loss of R waves in V2-3 with hyperacute waves V1-5. There’s no significant ST elevation but there are two forms of ST depression: deWinter T wave V3-5 and precordial swirl with ST depression V6 reciprocal to subtle STE in
ProtecT-2-D trial protocol: cardiovascular protection in patients with type 2 diabetes and established heart and/or vascular disease at a cardio-metabolic clinic—a randomized controlled trial
Cardiovascular Diabetology
JULY 7, 2024
Cardiovascular disease remains the primary cause of morbidity and mortality despite advancements in the treatment of patients with type 2 diabetes. Effective diabetes management extends beyond blood glucose co.
PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis
Frontiers in Cardiovascular Medicine
JULY 7, 2024
BackgroundAtherosclerotic cardiovascular disease (ASCVD), a leading cause of global fatalities, has inconsistent findings regarding the impact of muscle symptoms despite promising clinical trials involving PCSK9 inhibitors (PCSK9i) and siRNA as potential therapeutic options.MethodsThe databases EMBASE, PubMed, Web of Science, Cochrane, and ClinicalTrials.gov were thoroughly searched without any restrictions on language.
Genome-scale metabolic network of human carotid plaque reveals the pivotal role of glutamine/glutamate metabolism in macrophage modulating plaque inflammation and vulnerability
Cardiovascular Diabetology
JULY 7, 2024
Metabolism is increasingly recognized as a key regulator of the function and phenotype of the primary cellular constituents of the atherosclerotic vascular wall, including endothelial cells, smooth muscle cell.
RYR2 deficient human model identifies calcium handling and metabolic dysfunction impacting pharmacological responses
Frontiers in Cardiovascular Medicine
JULY 7, 2024
Creation of disease models utilizing hiPSCs in combination with CRISPR/Cas9 gene editing enable mechanistic insights into differential pharmacological responses. This allows translation of efficacy and safety findings from a healthy to a diseased state and provides a means to predict clinical outcome sooner during drug discovery. Calcium handling disturbances including reduced expression levels of the type 2 ryanodine receptor (RYR2) are linked to cardiac dysfunction; here we have created a RYR2
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
More Trending
Effect of flow-optimized pressure control ventilation-volume guaranteed (PCV-VG) on postoperative pulmonary complications: a consort study
Journal of Cardiothoracic Surgery
JULY 7, 2024
Background Postoperative pulmonary complications (PPCs) after one-lung ventilation (OLV) significantly impact patient prognosis and quality of life. Objective To study the impact of an optimal inspiratory flow rate on PPCs in thoracic surgery patients. Methods One hundred eight elective thoracic surgery patients were randomly assigned to 2 groups in this consort study (control group: n = 53 with a fixed inspiratory expiratory ratio of 1:2; and experimental group [flow rate optimizati
7 FDA Drug Decisions Anticipated Before the End of 2024
HCPLive
JULY 7, 2024
After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.
Million Hearts Model Reduces Cardiovascular Events Without Increasing Care Costs
Circulation
JULY 7, 2024
Circulation, Volume 150, Issue 2 , Page 162-164, July 9, 2024.
The association between heparin sensitivity index and postoperative blood loss in Chinese patients undergoing elective off-pump coronary artery bypass grafting: a single center retrospective study
Journal of Cardiothoracic Surgery
JULY 7, 2024
The heparin sensitivity index (HSI) is closely associated with perioperative ischemic events and increased blood loss in cardiac surgery. Previous studies have produced conflicting results. Therefore, this stu.
Correction to: Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target against Ischemic Heart Failure in Prediabetic Animals
Circulation
JULY 7, 2024
Circulation, Volume 150, Issue 2 , Page e63-e63, July 9, 2024.
Correction to: Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy
Circulation
JULY 7, 2024
Circulation, Volume 150, Issue 2 , Page e64-e64, July 9, 2024.
Correction to: C1q/Tumor Necrosis Factor-Related Protein-9 Regulates the Fate of Implanted Mesenchymal Stem Cells and Mobilizes Their Protective Effects Against Ischemic Heart Injury via Multiple Novel Signaling Pathways
Circulation
JULY 7, 2024
Circulation, Volume 150, Issue 2 , Page e62-e62, July 9, 2024.
Response by van Doorn et al to Letters Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”
Circulation
JULY 7, 2024
Circulation, Volume 150, Issue 2 , Page e30-e32, July 9, 2024.
Letter by Suwa et al Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”
Circulation
JULY 7, 2024
Circulation, Volume 150, Issue 2 , Page e27-e27, July 9, 2024.
Letter by Lin Regarding Article, “Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”
Circulation
JULY 7, 2024
Circulation, Volume 150, Issue 2 , Page e21-e22, July 9, 2024.
Let's personalize your content